Loading clinical trials...

Exercise, Fitness and Tumor Profiling in Breast Cancer Patients | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Exercise, Fitness and Tumor Profiling in Breast Cancer Patients

Integrative Profiling of Primary Breast Cancer on the Basis of Divergent Exercise Exposure

NCT03424915•Memorial Sloan Kettering Cancer Center

Summary

This study is designed to find out how engaging in regular exercise (or not) alters the biology of breast tumors as well as the normal tissue (if available) surrounding the tumor. The investigators hope that findings from this initial study will guide the design of future studies to examine how changes in exercise alter breast tumor biology.

Eligibility

Age

21 - 80 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Cohort 1: Breast Cancer Patients
•Ages 21-80 years
•Female
•Histologically confirmed ER receptor positive (\>1% staining), HER2 negative (FISH ratio \<1.8), untreated operable breast cancer
•Stage I to II disease
•Scheduled for surgical resection by any type of mastectomy or lumpectomy at MSK
•Tumor size ≥1cm by preoperative imaging or physical examination
•Categorization into self-reported exercise history exposure classifications as follows: (1) exercising: ≥120 minutes of vigorous-intensity exercise/wk for the past 12 months, and (2) sedentary (non-exercising): ≤ 30 minutes of moderate-intensity exercise/week for the past months using the Harvard Health Professionals survey.(34)
•Ability to read and understand English
•Willing and able to comply with requirements of the protocol
+11 more criteria

Exclusion Criteria

•Cohort 1:
•Received any form of neoadjuvant treatment
•Presence of any other concurrent, actively treated malignancy
•Presence of metastatic disease
•If performing a CPET, any of the following contraindications:
•* Acute myocardial infarction within 3-5 days of any planned study procedures;
•* Unstable angina
•* Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
•* Recurrent syncope
•* Active endocarditis
+41 more criteria

Locations (7)

Memorial Sloan Kettering Basking Ridge (Consent and Follow-up)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Consent and Follow-up)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Consent and Follow-up)

Montvale, New Jersey, United States

Memorial Sloan Kettering Commack (Consent and Follow-up)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Consent and Follow-up)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (Consent and Follow-up)

New York, New York, United States

Memorial Sloan Kettering Nassau (Consent and Follow-up)

Uniondale, New York, United States

Key Dates

Start Date

January 31, 2018

Primary Completion Date

January 1, 2027

Completion Date

January 1, 2027

Last Updated

February 4, 2026

Enrollment

ACTUAL participants

Conditions

Breast Cancer

Interventions

Harvard Health Professionals survey

BEHAVIORAL

Blood draw

OTHER

CPET Procedures

OTHER

stool sample

OTHER

Research Tissue sampling

PROCEDURE

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exercise, Fitness and Tumor Profiling in Breast Cancer Patients

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer